clinical trial · NCT03000569
A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
Biogen·phase2·completed·n = 29
Parkinson DiseaseSAGE-217LevodopaAntiparkinsonian Agent(s)
brief summary
This study assesses the safety, tolerability, pharmacokinetics and efficacy of SAGE-217 in 29 participants with moderate to severe Parkinson's Disease.
started
Nov 30, 2016
primary completion
Sep 11, 2017
completion
Sep 11, 2017
last updated
Nov 29, 2023
detailed description
Part A of the study is an open-label design with dosing of Levodopa for 3 days followed by SAGE-217 for 4 days.
Part B of the study is an open-label design with evening dosing of SAGE-217 for 7 days as an adjunct to antiparkinsonian agent(s).
This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.
official title
A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol